Tyagi, Pallavi
Juma, Zain
Hor, Yong Keen
Scott, Neil W.
Ionean, Andreea
Santiago, Cynthia
Funding for this research was provided by:
Bayer HealthCare
Novartis Pharmaceuticals UK Limited
Article History
Received: 28 January 2018
Accepted: 13 June 2018
First Online: 22 June 2018
Ethics approval and consent to participate
: Not applicable.This is a retrospective audit from data collected from electronic medical record. No patient identifiable data used.As per the UK Health Departments’ Governance Arrangements for Research Ethics Committees (GAfREC) guidance, “Research limited to secondary use of information previously collected in the course of normal care (without an intention to use it for research at the time of collection) is generally excluded from REC review, provided that the patients or service users are not identifiable to the research team in carrying out the research. This exception also applies to research undertaken by staff within a care team using information previously collected in the course of care for their own patients or clients, provided that data is anonymised or pseudonymised in conducting the research.”GAfREC is available at ExternalRef removed .
: Not applicable.
: The study was carried out independently however PT received travel grant from BAYER, UK to attend international meetings and AI and CS have received travel grants and speaker fees from Bayer and Novartis and acted as consultants for BAYER, UK.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.